PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-3.99%
Revenue decline while Medical - Pharmaceuticals median is 2.38%. Seth Klarman would investigate if market share loss is temporary.
-4.18%
Cost reduction while Medical - Pharmaceuticals median is 0.79%. Seth Klarman would investigate competitive advantage potential.
-3.25%
Gross profit decline while Medical - Pharmaceuticals median is 1.35%. Seth Klarman would investigate competitive position.
0.78%
Margin change of 0.78% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.68%
Other expenses change of 8.68% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
3.12%
Operating expenses growth 1.1-1.25x Medical - Pharmaceuticals median of 2.78%. John Neff would investigate control.
-2.95%
Total costs reduction while Medical - Pharmaceuticals median is 2.09%. Seth Klarman would investigate advantages.
-8.33%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
5.51%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 2.43%. Jim Chanos would check for overinvestment.
-15.99%
EBITDA decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-12.50%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-27.13%
Operating income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-24.11%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
2.50%
Other expenses change of 2.50% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.
-25.03%
Pre-tax income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-21.91%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-23.65%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-25.66%
Net income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-22.57%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-25.65%
EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-25.65%
Diluted EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.10%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.03%. Seth Klarman would investigate strategy.